We found that STAD patients with lower SERPINE1 levels exhibited significantly longer overall survival (OS) and disease-free survival (DFS) than those with higher SERPINE1 levels (p < 0.01). This evidence concerns the gene SERPINE1 and gastric adenocarcinoma.